|
業務類別
|
-- |
|
業務概覽
|
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin'slymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers. |
| 公司地址
| Ideongatan 1, Lund, SWE, SE-223 70 |
| 電話號碼
| +46 462868550 |
| 傳真號碼
| +46 462110806 |
| 公司網頁
| https://www.bioinvent.com |
| 員工數量
| 112 |
| Dr. Martin Welschof, PhD |
Chief Executive Officer |
-- |
04/04/2025 |
| Mr. Stefan Ericsson |
Chief Financial Officer |
-- |
04/04/2025 |
|
|
| Mr. Leonard Kruimer |
Chairman of the Board |
04/04/2025 |
| Dr. Bernd R. Seizinger, M.D.,PhD |
Independent Director |
04/04/2025 |
| Dr. Nanna Luneborg |
Independent Director |
04/04/2025 |
| Dr. Vincent Ossipow, C.F.A.,PhD |
Independent Director |
04/04/2025 |
| Mr. Kristoffer Bissessar |
Independent Director |
04/04/2025 |
| Dr. Thomas Hecht |
Independent Director |
04/04/2025 |
| Mrs. Natalie Brittenham Berner |
Director |
04/04/2025 |
| Mr. Tomas Wall |
Independent Director |
04/04/2025 |
| Ms. Laura Lassouw-Polman |
Independent Director |
04/04/2025 |
| Ms. Elin Birgersson |
Independent Director |
04/04/2025 |
|
|
|
|
